COVID-19: Novartis starts study on hyped malaria drug
Up to today, Novartis and Bayer announced donations of several millions of old antimalaria pills based on anecdotical reports of efficacy in COVID-19 patients. Now Novartis has started a study.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1324 entries already.
Entries by Thomas Gabrielczyk
COVID 19: Halix ready for vaccine production
/in News/by Thomas GabrielczykDutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford .
Carbios SAS publishes PET recycling technology
/in News/by Thomas GabrielczykFor years, French Carbios SAS has worked to set up a process that effectively depolymerizes PET, one of the most common plastics. Now its process has been published.
Mobidiags COVID-19 test okayed for emergency use
/in News/by Thomas GabrielczykMolecular diagnostics specialist Mobidiag Ltd has got emergency approval for its Amplidiag® COVID-19 molecular diagnostic test in Finland.
Researchers reconstruct SARS-CoV-2 evolution
/in News/by Thomas GabrielczykBritish researchers have tabled a phylogenetic tree showing different subtypes of SARS-CoV-2 developed in Asia, Europe and the US.
COVID-19: Solnatide approved for compassionate use
/in News/by Thomas GabrielczykAustrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
GE renamed Cytiva upon take-over by Danaher
/in News/by Thomas GabrielczykFollowing the completion of Danahers 19.5bn take-over of GE Healthcare Life Sciences, GEs CDMO arm is renamed Cytiva.
Making opoids more effective pain killers
/in News/by Thomas GabrielczykLow intrinsic efficacy can explain the reduced side effects of new agonists of the m-opioid receptor a British-Australian reseach team reports.
Apeptico gets EU grant for COVID-19 drug
/in News/by Thomas GabrielczykAustrian APEPTICO has got Horizon 2020 money for accelerated development and clinical use of Solnatide for the treatment of COVID-19 patients
CHMP greenlights Novartis Zolgensma
/in News/by Thomas GabrielczykThe European Medicines Agency EMA has backed eight medicines for approval at its virtual March 2020 meeting.